• A Biological Drug (PAS- YNS8) for Cancer Therapy (No. T4-1360)

    Scientist: Gideon Schreiber

    The human type I interferons number 12 distinct non-allelic alpha proteins, one beta, and one omega, all sharing the same structure and binding the same two cell surface receptors, IFNAR1 and IFNAR2. Interferons promote a wide range of activities, including antiviral activity, inhibition of cell growth and proliferation, ... Read more
  • A Method in Improving Survival and Expansion of Hematopoietic Stem Cells (No. T4-1874)

    Scientist: Idit Shachar

    hematopoietic cells. HSCs have the capacity to both self-renew and to differentiate, and they migrate from the bone marrow to the blood upon demand. Since HSCs can differentiate to a variety of cell types, including immune system cells, they have a huge therapeutic potential. Indeed, bone marrow transplantation is a comm ... Read more
  • A Novel Approach for Controlling Gene Expression (Arbirtium - a Novel approach) (No. T4-1847)

    Scientist: Rotem Sorek

    One of the challenges in the areas of synthetic biology and its clinical applications, is the capacity to control the induction of different genes, whether for the purpose of activating genetic circuits or inducing the expression of a specific protein. Present approaches are limited to the number of systems available, in ... Read more
  • A Novel Approach for Treating Cancer and Collagen-Associated Diseases by Using Anti-LOXL-2 Antibody (No. T4-1743)

    Scientist: Irit Sagi

    Disruption to the Extra-Cellular Matrix (ECM) is associated with many pathological conditions, such as various cancer types and tissue fibrosis, and also correlates with high tumor malignancy. Therefore, controlling ECM composition and morphology is considered a potential treatment for cancer and other ECM-associated dis ... Read more
  • A Novel Method for Detecting Activation of Necroptosis via Exosome Analysis (No. T4-1839)

    Scientist: David Wallach

    Numerous medical conditions are related to inflammation, such as pancreatitis, psoriasis, inflammatory bowel disease, atherosclerosis, neurodegeneration, and more. However, determination of inflammation in the body, especially at early stages of a pathology is difficult to assess. Therefore, there is a great clinical nee ... Read more
  • A Novel Method for Treating Drug-Resistant Lung Cancer Using a Combination of Antibodies (No. T4-1774)

    Scientist: Yosef Yarden

    A novel method for treating tyrosine kinase inhibitor (TKI)-resistant cancer, by using a combination of three different antibodies. Lung cancer is known as one of the most fatal forms of cancer. Notably, standard treatments for other cancer types (e.g. TKIs and mAbs), have shown only a limited effect on this specific mal ... Read more
  • A Novel Method of Preventing or Treating Secondary Infections by Inhibition of Membrane Type I Matrix-Metalloproteinase-1 (No. T4-1790)

    Scientist: Irit Sagi

    A novel method of preventing secondary infections, by inhibition of membrane type I matrix-metalloproteinase-1 (MT1-MMP), which reduces degradation of the extra-cellular matrix. Pathogens that infect the respiratory system are the cause of some of the most dangerous infections, especially for vulnerable populations such ... Read more
  • A Novel Method of Treating Cancer by Targeting EGFR Ligand Amphiregulin (No. T4-1776)

    Scientist: Yosef Yarden

    A novel method for treating ovarian cancer by intercepting the EGFR ligand amphiregulin, when elevated expression levels are found in a patient. Ovarian cancer represents a relatively common type of cancer that affects women. However, the primary therapeutic option for ovarian cancer has remained the same since the 1970 ... Read more
  • A Novel Technique to Produce Large Quantities of Therapeutic T cells (No. T4-1810)

    Scientist: Benjamin Geiger

    Culturing and expanding T cells ex-vivo, while retaining their functionality, is an essential factor for the development of cutting-edge immunotherapies. A major problem frequently faced by physicians is the low number of T cells available for adoptive immunotherapy, and the difficulty to retain their functionality follo ... Read more
  • A TACE Inhibitor (ADAM17) (No. T4-1628)

    Scientist: Irit Sagi

    New generation of superior nature-inspired therapeutics for treating inflammation.Inflammation is characterized by elevated levels of TNF-?. Neutralizing TNF-? activity was shown to be beneficial for patients with chronic autoimmune inflammatory diseases such as rheumatoid arthritis (RA) and inflammatory bowel disease (I ... Read more


Subscribe to Pharmaceuticals